Cargando…
Association between the Use of Dipeptidyl Peptidase 4 Inhibitors and the Risk of Dementia among Patients with Type 2 Diabetes in Taiwan
Study Objectives: Diabetes mellitus per se and its related therapy have been frequently associated with an increased risk of developing dementia. However, studies that explored the risk of dementia from the use of the novel oral antidiabetic medication dipeptidyl peptidase 4 inhibitor (DPP-4i) have...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141309/ https://www.ncbi.nlm.nih.gov/pubmed/32121372 http://dx.doi.org/10.3390/jcm9030660 |
_version_ | 1783519169838317568 |
---|---|
author | Chen, Kuan-Chan Chung, Chi-Hsiang Lu, Chieh-Hua Tzeng, Nian-Sheng Lee, Chien-Hsing Su, Sheng-Chiang Kuo, Feng-Chih Liu, Jhih-Syuan Hsieh, Chang-Hsun Chien, Wu-Chien |
author_facet | Chen, Kuan-Chan Chung, Chi-Hsiang Lu, Chieh-Hua Tzeng, Nian-Sheng Lee, Chien-Hsing Su, Sheng-Chiang Kuo, Feng-Chih Liu, Jhih-Syuan Hsieh, Chang-Hsun Chien, Wu-Chien |
author_sort | Chen, Kuan-Chan |
collection | PubMed |
description | Study Objectives: Diabetes mellitus per se and its related therapy have been frequently associated with an increased risk of developing dementia. However, studies that explored the risk of dementia from the use of the novel oral antidiabetic medication dipeptidyl peptidase 4 inhibitor (DPP-4i) have been limited, especially in Asian populations. The present study aimed to determine the effect of DPP-4i on the subsequent risk of dementia among patients with type 2 diabetes (T2D) in Taiwan. Methods: This study utilized data from the Longitudinal Health Insurance Database between 2008 and 2015. We enrolled 2903 patients aged ≥50 years, who were on DPP-4i for a diagnosis of T2D and had no dementia. A total of 11,612 subjects were included and compared with a propensity score-matched control group who did not use DPP-4i (non-DPP-4i group). Survival analysis was performed to estimate and compare the risk of dementia—including Alzheimer’s disease, vascular dementia, and other dementia types—between the two groups. Results: Both groups had a mean age of 68 years, had a preponderance of women (61.8%), and were followed up for a mean duration of 7 years. The risk of all-cause dementia was significantly lower in the DPP-4i group than in the non-DPP-4i group (hazard ratio (HR) 0.798; 95% confidence interval (CI) 0.681–0.883; p < 0.001), with a class effect. This trend was particularly observed for vascular dementia (HR 0.575; 95% CI 0.404–0.681; p < 0.001), but not in Alzheimer’s disease (HR 0.891; 95% CI 0.712–1.265; p = 0.297). The Kaplan–Meier analysis showed that the preventive effect on dementia was positively correlated with the cumulative dose of DPP-4i. Conclusions: DPP-4i decreased the risk of dementia with a class effect, especially vascular dementia, but not in Alzheimer’s disease. Our results provide important information on the drug choice when managing patients with T2D in clinical practice. |
format | Online Article Text |
id | pubmed-7141309 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-71413092020-04-10 Association between the Use of Dipeptidyl Peptidase 4 Inhibitors and the Risk of Dementia among Patients with Type 2 Diabetes in Taiwan Chen, Kuan-Chan Chung, Chi-Hsiang Lu, Chieh-Hua Tzeng, Nian-Sheng Lee, Chien-Hsing Su, Sheng-Chiang Kuo, Feng-Chih Liu, Jhih-Syuan Hsieh, Chang-Hsun Chien, Wu-Chien J Clin Med Article Study Objectives: Diabetes mellitus per se and its related therapy have been frequently associated with an increased risk of developing dementia. However, studies that explored the risk of dementia from the use of the novel oral antidiabetic medication dipeptidyl peptidase 4 inhibitor (DPP-4i) have been limited, especially in Asian populations. The present study aimed to determine the effect of DPP-4i on the subsequent risk of dementia among patients with type 2 diabetes (T2D) in Taiwan. Methods: This study utilized data from the Longitudinal Health Insurance Database between 2008 and 2015. We enrolled 2903 patients aged ≥50 years, who were on DPP-4i for a diagnosis of T2D and had no dementia. A total of 11,612 subjects were included and compared with a propensity score-matched control group who did not use DPP-4i (non-DPP-4i group). Survival analysis was performed to estimate and compare the risk of dementia—including Alzheimer’s disease, vascular dementia, and other dementia types—between the two groups. Results: Both groups had a mean age of 68 years, had a preponderance of women (61.8%), and were followed up for a mean duration of 7 years. The risk of all-cause dementia was significantly lower in the DPP-4i group than in the non-DPP-4i group (hazard ratio (HR) 0.798; 95% confidence interval (CI) 0.681–0.883; p < 0.001), with a class effect. This trend was particularly observed for vascular dementia (HR 0.575; 95% CI 0.404–0.681; p < 0.001), but not in Alzheimer’s disease (HR 0.891; 95% CI 0.712–1.265; p = 0.297). The Kaplan–Meier analysis showed that the preventive effect on dementia was positively correlated with the cumulative dose of DPP-4i. Conclusions: DPP-4i decreased the risk of dementia with a class effect, especially vascular dementia, but not in Alzheimer’s disease. Our results provide important information on the drug choice when managing patients with T2D in clinical practice. MDPI 2020-02-29 /pmc/articles/PMC7141309/ /pubmed/32121372 http://dx.doi.org/10.3390/jcm9030660 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Chen, Kuan-Chan Chung, Chi-Hsiang Lu, Chieh-Hua Tzeng, Nian-Sheng Lee, Chien-Hsing Su, Sheng-Chiang Kuo, Feng-Chih Liu, Jhih-Syuan Hsieh, Chang-Hsun Chien, Wu-Chien Association between the Use of Dipeptidyl Peptidase 4 Inhibitors and the Risk of Dementia among Patients with Type 2 Diabetes in Taiwan |
title | Association between the Use of Dipeptidyl Peptidase 4 Inhibitors and the Risk of Dementia among Patients with Type 2 Diabetes in Taiwan |
title_full | Association between the Use of Dipeptidyl Peptidase 4 Inhibitors and the Risk of Dementia among Patients with Type 2 Diabetes in Taiwan |
title_fullStr | Association between the Use of Dipeptidyl Peptidase 4 Inhibitors and the Risk of Dementia among Patients with Type 2 Diabetes in Taiwan |
title_full_unstemmed | Association between the Use of Dipeptidyl Peptidase 4 Inhibitors and the Risk of Dementia among Patients with Type 2 Diabetes in Taiwan |
title_short | Association between the Use of Dipeptidyl Peptidase 4 Inhibitors and the Risk of Dementia among Patients with Type 2 Diabetes in Taiwan |
title_sort | association between the use of dipeptidyl peptidase 4 inhibitors and the risk of dementia among patients with type 2 diabetes in taiwan |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141309/ https://www.ncbi.nlm.nih.gov/pubmed/32121372 http://dx.doi.org/10.3390/jcm9030660 |
work_keys_str_mv | AT chenkuanchan associationbetweentheuseofdipeptidylpeptidase4inhibitorsandtheriskofdementiaamongpatientswithtype2diabetesintaiwan AT chungchihsiang associationbetweentheuseofdipeptidylpeptidase4inhibitorsandtheriskofdementiaamongpatientswithtype2diabetesintaiwan AT luchiehhua associationbetweentheuseofdipeptidylpeptidase4inhibitorsandtheriskofdementiaamongpatientswithtype2diabetesintaiwan AT tzengniansheng associationbetweentheuseofdipeptidylpeptidase4inhibitorsandtheriskofdementiaamongpatientswithtype2diabetesintaiwan AT leechienhsing associationbetweentheuseofdipeptidylpeptidase4inhibitorsandtheriskofdementiaamongpatientswithtype2diabetesintaiwan AT sushengchiang associationbetweentheuseofdipeptidylpeptidase4inhibitorsandtheriskofdementiaamongpatientswithtype2diabetesintaiwan AT kuofengchih associationbetweentheuseofdipeptidylpeptidase4inhibitorsandtheriskofdementiaamongpatientswithtype2diabetesintaiwan AT liujhihsyuan associationbetweentheuseofdipeptidylpeptidase4inhibitorsandtheriskofdementiaamongpatientswithtype2diabetesintaiwan AT hsiehchanghsun associationbetweentheuseofdipeptidylpeptidase4inhibitorsandtheriskofdementiaamongpatientswithtype2diabetesintaiwan AT chienwuchien associationbetweentheuseofdipeptidylpeptidase4inhibitorsandtheriskofdementiaamongpatientswithtype2diabetesintaiwan |